Host-Microbe Bioinformatics Post-Doctoral Fellow GlaxoSmithKline, Collegeville, Pennsylvania
In GlaxoSmithKline R&D (http://www.gsk.com/research.html), computational biologists have a broad and essential role in drug discovery through the integrative analysis of internal and external biomedical data, combining strong computational skills with biological insight. Our work results in real impacts on new therapeutic approaches to highly important diseases of unmet medical need.
This Early Talent postdoctoral fellowship (2 year) with the Computational Biology Department involves working across multiple therapy areas on the interactions between the microbiome, pathogens and human host immunity. The roles of both beneficial and pathogenic microbes on human host pathways are being increasingly linked to the occurrences of many chronic and infectious diseases. With the rapid expansion of multiple genomics platforms, there is a significant opportunity for the development and application of new computational approaches to identify novel human gene targets modulated by microbial interactions for the treatment of infectious, respiratory, inflammatory and other diseases. The successful candidate will provide computational biology insight and analyses to interdisciplinary teams of drug discovery scientists. A key role will be to develop and lead novel computational biology studies along with writing of manuscripts for high impact scientific journals. This is an excellent opportunity for those interested in applying their bioinformatics skills to translational and transformative medicine projects in a large pharmaceutical R&D organization. As a post doctoral fellow with GSK, you will be working closely with multi-disciplinary teams of biologists, chemists, physicians, clinical scientists and computational biologists to develop novel approaches for the analysis of large unique clinical datasets relevant to respiratory diseases with the aim to support precision medicine discovery efforts. More information about microbiome research at GSK can be found at: http://www.gsk.com/en-gb/behind-the-science/innovation/take-a-deep-breath-your-lung-microbiome-will-appreciate-it/ GSK provides a very supportive environment for early talent career development with a special emphasis on the post-doctoral fellow community. We strongly encourage interactions with the external scientific community and there will be excellent opportunities for publications and conference presentations. Moreover, this position provides a real-life experience in a dynamic global pharmaceutical R&D organization. It is an unrivalled opportunity for applying your computational biology and biomedical skills to help develop cutting edge disease therapeutics. For more information about GSK post-doctoral fellowships, see: http://www.gsk.com/en-gb/careers/postgraduates/randd-postdoctoral-global-training-programme/
• Recent PhD in bioinformatics / computational science / biomedical engineering/ biological sciences or equivalent research experience. • Demonstrated skills to programmatically collect, combine, mine and analyze complex biological data. • Experience in the analysis of microbial and human genomic datasets especially from Next Generation DNA sequencing platforms. • Good verbal and written communication skills and ability to work well with multi-disciplinary teams. • Strong interest in publication in peer reviewed journals.
Selected recent publications by GSK Computational Biology and Respiratory Clinical Discovery (*PDF or graduate student led papers)
- *Wang Z et al. 2016. Lung microbiome dynamics in chronic obstructive pulmonary disease exacerbations. European Respiratory Journal. 47:1082-92.
- *Saha S et al. 2016. Human microbial metabolites as a source of new drugs. Drug Discovery Today. 21: 692-698.
- Brown JR et al. 2013 Translating the human microbiome. Nature Biotechnology 31:304–308.
- *Smith DB et al. 2013. Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data. PLoS One 8:e75607.
- *Martínez-Jiménez F et al. 2013. Target prediction for an open access set of compounds active against Mycobacterium tuberculosis. PLoS Computational Biology 9:e1003253.
- Rajpal DK, Brown JR. 2013. The microbiome as a therapeutic target for metabolic diseases. Drug Development Research 74:376-394.
- *Smith SB, et al. 2012. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS One 7:e33174.
Please submit your application to: http://www.gsk.com/en-gb/careers/ and requisition no. WD78880